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© 2012 The Japan Society of Histochemistry and Antigen retrieval (AR) and ultra-super sensitive immunohistochemistry (ultra-IHC) have been
established for application to archival human pathology specimens. The original ultra-IHC
was the ImmunoMax method or the catalyzed signal amplification system (ImmunoMax/CSA
method), comprising the streptavidin-biotin complex (sABC) method and catalyzed reporter
deposition (CARD) reaction with visualization of its deposition. By introducing procedures to
diminish non-specific staining in the original ultra-IHC method, we developed the modified
ImmunoMax/CSA method with AR heating sections in an AR solution (heating-AR). The
heating-AR and modified ImmunoMax/CSA method visualized expression of the predomi-
nantly simple present form of HTLV-1 proviral DNA pX region p40Tax protein (Tax) in adult
T-cell leukemia/lymphoma (ATLL) cells in archival pathology specimens in approximately
75% of cases. The simple present form of Tax detected exhibited a close relation with ATLL
cell proliferation. We also established a new simplified CSA (nsCSA) system by replacing
the sABC method with the secondary antibody- and horse radish peroxidase-labeled polymer
reagent method, introducing the pretreatments blocking non-specific binding of secondary
antibody reagent, and diminishing the diffusion of deposition in the CARD reaction. Combined
with AR treating sections with proteinase K solution (enzymatic-AR), the nsCSA system
visualized granular immunostaining of the complex present form of Tax in a small number
of ATLL cells in most cases, presenting the possibility of etiological pathological diagnosis
of ATLL and suggesting that the complex present form of Tax-positive ATLL cells were young
cells derived from ATLL stem cells. The heating-AR and ultra-IHC detected physiological
expression of the p53 protein and its probable phosphorylation by Tax in peripheral blood
mononuclear cells of peripheral blood tissue specimens from HTLV-1 carriers, as well as
physiological and pathological expression of the molecules involved with G1 phase
progression and G1–S phase transition (E2F-1, E2F-4, DP-1, and cyclin E) in ATLL and
peripheral T-cell lymphoma cells. The ultra-IHC with AR is useful for etiological pathological
diagnosis of ATLL since HTLV-1 pathogenicity depends on that of Tax, and can be a useful
tool for studies translating advanced molecular biology and pathology to human pathology.
Key words: ultra-super sensitive immunohistochemistry, HTLV-1, p53 protein, cell cycle, 
adult T-cell leukemia/lymphoma (ATLL)
I. Introduction
Adult T-cell leukemia/lymphoma (ATLL) is a type of
peripheral T-cell leukemia/lymphoma (PTCL) that is causedHasui et al. 84
by human T-lymphotropic virus type 1 (HTLV-1) [96].
ATLL occurs in the lifetime of 2 to 5% of HTLV-1 carriers
[4]. ATLL is subcategorized clinically into smoldering,
including cutaneous type, chronic and acute leukemia, and
lymphoma types [89]. Most ATLL patients have anti-HTLV-
1 antibodies [36] when ATLL cells exhibit monoclonal
integration of HTLV-1 proviral DNA [109, 111].
In the natural history of HTLV-1 infection, following
latent infection spanning more than 30 years from the initial
infection in the perinatal period (Fig. 1) and based on
virological, molecular biological and immunological under-
standing of HTLV-1 infection, early-phase ATLL cells with
neoplastic properties dependent on the HTLV-1 proviral
DNA pX region p40Tax protein (Tax) [42, 70, 80, 93, 101,
110] appear under the effects of external and internal
mutagens [19, 76, 84] following the accumulation of
mutations induced by repeated Tax expression [18] in the
background of persistent proliferation of HTLV-1-infected
T-cells, which is probably induced by HTLV-1 basic leucine
zipper (HBZ) mRNA [64, 65]. Then, late-phase ATLL cells
with neoplastic properties independent of Tax appear when
mutation has progressed in the host cell DNA and HTLV-
1 proviral DNA including pX p40Tax DNA sequence [19].
ATLL cells exhibit the CD4+ CD25+ forkhead box
protein P3+ (Foxp3+) phenotype of regulatory T-cells [108].
PTCL in a patient with anti-HTLV-1 antibodies or with
clinicopathological information of HTLV-1 proviral DNA
integration is diagnosed practically as ATLL. On the other
hand, etiological pathological diagnosis of ATLL is ex-
pected based on immunohistochemistry (IHC) detecting of
Fig. 1. Pathogenicity of human T-lymphotropic virus type 1 (HTLV-1). ATLL is thought to be caused by pathogenicity of the HTLV-1 proviral
DNA pX region p40Tax protein (Tax) and effects of external and internal mutagens. Recently, HTLV-1 basic leucine zipper (HBZ) mRNA
from the HTLV-1 proviral DNA minus strand is regarded to cause ATLL independently of Tax. A) Latent phase HTLV-1 infection: Tax
synthesis is modulated by HTLV-proviral DNA pX region p27Rex protein (Rex). Tax trans-activates and -suppresses host cell genes. HBZ
mRNA propels proliferation of the host cells through E2F-1 signaling to the cell cycle. Internal and external mutagens affect host cell genes
when APOBEC3G is one of the internal mutagens in activated T-cells. B) Anti-HTLV-1 immunity: Anti-HTLV-1 immunity would eliminate
HTLV-1 infected T-cells. C) Early phase ATLL: Neoplastic proliferation of early ATLL cells depends on Tax in the background of the effects
of HBZ mRNA, chromosomal changes and mutations. D) Late phase ATLL: Accumulation of chromosomal changes and mutations with and
without the effects of Tax, APOBEC3G and the other mutagens confer neoplastic properties to early phase ATLL cells. Tax may disappear
and its DNA might be destroyed in most late phase ATLL cells. E) Development of a Tax-independent T-cell neoplasm: Depending on the
chromosomal changes and mutations induced by the external and internal mutagens and possibly by HBZ mRNA, HTLV-1 infected T-cells
may develop into a Tax-independent T-cell neoplasm.Ultra-Super Sensitive IHC Applied to Etiological Study of ATLL 85
Fig. 2. Products of super and ultra-super sensitive immunohistochemistry (IHC) and pretreatments for ultra-super sensitive IHC (ultra-IHC).
Differences among enzyme-labeled antibody indirect methods can be observed in their products and in each method’s pretreatments. A) Super
sensitive IHC (ordinary-IHC) methods related to ultra-IHC are a) classic enzyme-labeled secondary antibody method, b) avidin (streptavidin)-
biotin complex method (ABC/sABC method), c) horse radish peroxidase (HRP)-labeled streptavidin-biotin complex method (LSAB method,
and d) HRP- and secondary antibody-labeled polymer reagent method (Polymer method). B) Ultra-IHC by means of catalyzed reporter
deposition (CARD) reaction. The original ImmunoMax/CSA method (e) comprises the sABC method (b) and a CARD reaction with detection
of deposited biotinylated tyramide by the LSAB method (c). Dako CSA II system (f), a biotin-free system, comprises the enzyme-labeled
secondary antibody method (a) and CARD reaction with detection of deposited FITC-labeled tyramide with HRP-labeled anti-FITC antibody.
The new simplified CSA system (g) comprises the polymer method and CARD reaction with detection of deposited biotinylated tyramide by
the LSAB method (c) or with detection of deposited FITC-labeled tyramide with HRP-labeled anti-FITC antibody. C) Pretreatment for
ultra-IHC with the CARD reaction. The original ImmunoMax/CSA method is equipped with pretreatments for endogenous peroxidase and
non-specific binding of the primary antibody. The modified ImmunoMax/CSA method introduces masking of endogenous biotin in itself. The
Dako CSA II system is not equipped with additional pretreatments besides those available in the original ImmunoMax/CSA method. The new
simplified CSA system is equipped with additional pretreatments for non-specific binding of the secondary antibody and non-specific staining
in CARD reaction.Hasui et al. 86
Tax, HTLV-1 proviral DNA pX p27Rex protein (Rex) and
HBZ mRNA/protein in PTCL cells. However, the amount
of Tax, Rex and HBZ protein in ATLL cells is too small
to be detected by ordinary super sensitive enzyme-labeled
antibody methods of IHC (ordinary-IHC) such as avidin/
streptavidin-biotin complex (ABC/sABC, Fig. 2b), labeled
streptavidin-biotin complex method (LSAB, Fig. 2c), and
polymer methods (Fig. 2d). Therefore, these proteins should
be detected by ultra-super sensitive IHC (ultra-IHC) com-
prising an indirect enzyme-labeled antibody method and
catalyzed reporter deposition (CARD) reaction (Fig. 2e).
Some ultra-IHC kits are commercially available but suffer
from strong non-specific staining. We have succeeded in
developing ultra-IHC of Tax and Rex on routine paraffin
sections of ATLL [30, 31, 35, 62], solving the problems
that cause the strong non-specific staining.
This review describes our development of the ultra-
IHC and its application, which employs anti-HTLV-1-
related antibodies, to the pathological diagnosis of ATLL
and the analysis of ATLL oncogenesis and pathogenesis.
II. Development of Ultra-IHC
Antigen retrieval (AR) heating sections in an AR
solution such as 0.01 M citrate buffer, pH 6.0 (heating-AR)
heralded the era of so-called paraffin section IHC in the
1990s [86–88]. Currently, many antigens can be detected in
archival human pathology specimens by combining heating-
AR with ordinary-IHC. In ultra-IHC, heating-AR retrieves
larger amounts of antigen based on autoclaving (121°C for
5 min), pressure cooking (for 10 min after boiling) and
microwaving (3 times heating for 1 min) but also yields
more non-specific staining, whereas heating-AR in 4  M
urea solution demonstrated less non-specific staining than
heating in 0.01 M citrate buffer [27, 30]. Since the J
chain in immunoglobulins A and M and amyloid protein
are unmasked by rinsing sections in a solution of highly
concentrated denaturing reagent such as urea at 4°C
overnight [17, 71], the heating-AR in 4  M urea is also
expected to denature and expose antigens to the antibody.
Recently, heating-AR has often been performed independ-
ently of the AR solution pH [104]. On the other hand, AR
treating sections with an enzyme such as proteinase K
(enzymatic-AR) is expected to enable visualization of
molecules that form complexes or bind with other proteins
and DNA, etc. by partly digesting the molecule/tissue
complexes obscuring the target molecules [50].
Ultra-IHC was introduced in the field of surgical
pathology as the original ImmunoMax/CSA method [67]
(Fig. 2e), comprising heating-AR, sABC method (Fig. 2b),
CARD reaction (Fig. 2B) and detection of the CARD
deposition by LSAB method (Fig. 2c). The ImmunoMax
method employed serum solutions such as phosphate buf-
fer saline (PBS) containing 8% horse serum or 8% human
AB type serum for blocking non-specific binding (Protein
block) of the primary antibody, while CSA system used a
serum-free solution such as PBS containing 0.25% casein
Table 1. Protocols of ultra-super sensitive immunohistochemistry




b First inactivation of endogenous peroxidase (IEP) rinsing 
sections in methanol containing 0.3% H2O2 for 20 min.
c Antigen retrieval
d Rinse sections in phosphate buffer saline (PBS).
Set slides to the autostainer.
1 Second IEP rinsing sections in PBS containing 3% H2O2 
for 5 min.
2–4 3 times Rinse1
5 *Protein block suppressing non-specific binding of 
primary antibody for 5 min.
6 Primary antibody reaction for 15 min.
7–9 3 times Rinse1
10 Endogenous biotin mask (1) rinsing in avidin solution for 
15 min.
11–13 3 times Rinse1
14 Endogenous biotin mask (2) rinsing in biotin solution for 
15 min.
15–17 3 times Rinse1
18 **Protein block suppressing non-specific binding of 
secondary antibody for 5 min.
19 Biotinylated secondary antibody reaction for 15 min.
20–22 3 times Rinse1
23 Horse radish peroxidase (HRP)-labeled streptavidin 
reaction for 15 min.
24–26 3 times Rinse1
27 ***Protein block suppressing diffusion of catalyzed 
tyramide in the Catalyzed reporter deposition (CARD) 
reaction for 1 min.
28 CARD reaction for 15 min.
29–30 2 times Rinse2
31 HRP-labeled streptavidin reaction for 15 min
32–33 2 times Rinse2
34 H2O2-Diaminobenzidine (DAB) reaction for 5 min.
35 Rinse with distilled water to stop the DAB reaction.
36 Counterstaining of nuclei
37 Rinse with distilled water.
Remove slides from the autostainer.
Dehydrate slides and mount section with plastic medium.
Rinse1: Rinse with Tris buffer saline containing 0.1% Tween 20
(TBST) warmed at 35°C.
Rinse2: Rinse with TBST warmed at 35°C. But the rinsing buffer is
PBS at room temperature in a case when a rinsing buffer can be
changed by a semi-autostainer (MicroProbeTM, Fisher Scientific Co.).
*: Protein block employs PBS containing 0.25% casein (Dako) with
8% horse serum.
**: Protein block employs PBS containing 0.25% casein (Dako) with
8% goat serum.
***: Protein block employs PBS containing 0.25% casein (Dako) or
PBS with 3% BSA.
Steps 18 and 27 were inserted according to the new simplified CSA
system (Table 1C).Ultra-Super Sensitive IHC Applied to Etiological Study of ATLL 87
for Protein block. As molecular biology developed, the
amounts of molecules traditionally targeted by IHC, such
as those of signal transduction molecules and phosphoryl-
ated functional proteins, became too minute to be visualized
by ordinary-IHC. Then, the ultra-IHC was expected to
detect much smaller amounts of molecules, amplifying the
ordinary-IHC signals a thousand times through the CARD
reaction.
Unfortunately, the original ImmunoMax/CSA method
required 2 times horse-radish peroxidase (HRP) reaction in
Table 1. Continued (1).





c Rinse sections in PBS
Set slides to the autostainer.
1 inactivation of endogenous peroxidase rinsing sections in 
methanol containing 0.3% H2O2 for 20 min.
2–4 3 times Rinse1
5 *Protein block for 5 min.
6 Primary antibody reaction for 15 min.
7–9 3 times Rinse1
10 **Protein block for 5 min.
11 HRP-labeled secondary antibody reaction for 15 min.
12–14 3 times Rinse1
15 ***Protein block for 1 to 5 min.
16 CARD reaction of fluorescein isothiocyanate (FITC)-
labeled tyramide for 30 min.
17–18 2 times Rinse2
19 HRP-labeled anti-FITC antibody reaction for 30 min.
20–21 2 times Rinse2
22 H2O2-DAB reaction for 5 min.
23 Rinse with distilled water to stop the DAB reaction.
24 Counterstaining of nuclei
25 Rinse with distilled water.
Remove slides from the autostainer.
Dehydrate slides and mount section with plastic medium.
Steps 10 and 15 are inserted according to the new simplified CSA
system (Table 1C).
Rinse1: Rinse with Tris buffer saline containing 0.1% Tween 20
(TBST) warmed at 35°C.
Rinse2: Rinse with TBST warmed at 35°C. But the rinsing buffer is
PBS at room temperature in a case when a rinsing buffer can be
changed by a semi-autostainer (MicroProbeTM, Fisher Scientific Co.).
Rinse: Post-reaction wash with TBST at room temperature.
*: Protein block employs PBS containing 0.25% casein (Dako) with
8% horse serum.
**: Protein block employs PBS containing 0.25% casein (Dako) with
8% goat serum.
***: Protein block suppresses diffusion of depositing FITC-labeled
tyramide in the CARD reaction, pre-treating sections with PBS
containing 3% polyethylene glycol (PEG) #20000 and 0.1% Tween
20 or with PBS containing 0.3% BSA and 0.1% Tween 20.
Table 1. Continued (2).
C) New simplified CSA system (nsCSA system)
Step Work
a Deparaffinization.
b First inactivation of endogenous peroxidase (IEP) rinsing 
sections in methanol containing 0.3% H2O2 for 20 min.
c Antigen retrieval
d Rinse sections in PBS
Set slides to the autostainer.
1 Second IEP rinsing sections in PBS containing 3% H2O2 
for 5 min.
2–4 3 times Rinse1
5 *Protein block for 5 min.
6 Primary antibody reaction for 15 min.
7–9 3 times Rinse1
10 **Protein block for 5 min.
11 HRP- and secondary antibody-labeled polymer 
reagent reaction for 15 min.
12–14 3 times Rinse1 (Go to step15)
15 ***Protein block for 1 min.
16 CARD reaction of biotinylated tyramide for 15 min.
17–18 2 times Rinse2
19 HRP-labeled streptavidin reaction for 15 min.
20–21 2 times Rinse2 (Go to step 22)
In a case employing FITC-labeled tyramide.
15 ****Protein block for 1 min.
16 CARD reaction of FITC-labeled tyramide for 30 min.
17–18 2 times Rinse2
19 HRP-labeled anti-FITC antibody reaction for 30 min.
20–21 2 times Rinse2 (Go to step 22)
22 H2O2-DAB reaction for 5 min.
23 Rinse with distilled water to stop the DAB reaction.
24 Counterstaining of nuclei
25 Rinse with distilled water.
Remove slides from the autostainer.
Dehydrate slide and mount section with plastic medium.
Rinse1: Rinse with Tris buffer saline containing 0.1% Tween 20
(TBST) warmed at 35°C.
Rinse2: Rinse with TBST warmed at 35°C. But the rinsing buffer is
PBS at room temperature in a case when a rinsing buffer can be
changed by a semi-autostainer (MicroProbeTM, Fisher Scientific Co.).
*Protein block: Protein block suppresses non-specific binding of
primary antibody, rinsing sections in PBS containing 0.25% casein
(Dako) with 8% horse serum or in PBS containing 3% BSA and 8%
horse or goat serum
**Protein block: Protein block suppresses non-specific binding of
secondary antibody, rinsing sections in PBS containing 0.25% casein
(Dako) with 8% goat serum or in PBS containing 3% BSA and 8%
goat serum.
***Protein block: Protein block suppresses diffusion of depositing
biotinylated tyramide in the CARD reaction, pre-treating sections with
PBS containing 0.25% casein (Dako) or PBS with 3% BSA.
****Protein block: Protein block suppresses diffusion of depositing
FITC-labeled tyramide in the CARD reaction, pre-treating sections
with PBS containing 3% polyethylene glycol (PEG) #20000 and 0.1%
Tween 20 or with PBS containing 0.3% BSA and 0.1% Tween 20.Hasui et al. 88
the CARD reaction and diaminobenzidine (DAB)-H2O2
reaction for visualization and 2 times biotin-streptavidin
binding reaction in the sABC method and in the LSAB
method detecting deposited catalyzed tyramide. Moreover,
its post-reaction wash appeared incomplete. Therefore,
the original ImmunoMax/CSA method (Fig. 2C, Original
ImmunoMax/CSA method) amplified an extremely low
level of residual activity of endogenous peroxidase, a
rather small amount of endogenous biotin, and a trace level
of residual reaction reagents into a huge amount of non-
specific staining. Thus, the modified ImmunoMax/CSA
method (Table 1A) was designed [30] to diminish non-
specific staining by introducing double inactivation of endo-
genous peroxidase before and after AR, endogenous biotin
mask treating sections with avidin and biotin solutions
between the primary antibody and biotinylated secondary
antibody reactions (Fig. 2C, Modified ImmunoMax/CSA
method), and the post-reaction wash (PR wash) 3 times in
Tris-buffered saline containing 0.5% Tween 20 (TBST)
warmed to 35°C [30]. The modified ImmunoMax/CSA
method employed PBS containing 8% horse serum and
0.25% casein for Protein block before the primary antibody
reaction. Biotinylated tyramide deposited in the CARD
reaction was washed out by rinsing 3 times in the warmed
TBST so the PR wash following the CARD reaction was
defined as rinse twice in PBS at room temperature when
the PR wash solution could be changed [30]. Finally, the
modified ImmunoMax/CSA method comprised 37 steps in
an autostainer (Table 1A), where 2 steps of Protein block
for the secondary antibody reaction (step 18, Table 1A)
and pretreatment for the reaction (step 27, Table 1A) were
those employed in the new simplified CSA (nsCSA) system
(Table 1C).
However, non-specific staining persisted somewhat in
the modified ImmunoMax/CSA method, and varied with
each case. The positive staining of the modified Immuno-
Max/CSA method was evaluated in comparison with staining
performed without the primary antibody reaction (negative
control staining). To prevent non-specific staining caused
by endogenous biotin, Dako supplied a CSA II system
(Table 1B) to replace the sABC method (Fig. 2b) and the
biotinylated tyramide-CARD reaction with HRP-labeled
secondary antibody method (Fig. 2a) and the fluorescein
isothiocyanate (FITC)-labeled tyramide-CARD reaction
(Fig. 2f) but did not equip the Protein block to suppress
non-specific binding of the secondary antibody and the
pretreatment to suppress the diffusion of catalyzed FITC-
labeled tyramide (Fig. 2C, Dako CSA II system). Then,
non-specific background staining with the Dako CSA II
system was quite high. On the other hand, we developed
new simplified CSA system (nsCSA system) (Table 1C,
Fig. 2g), replacing the sABC method (Fig. 2b) with the
HRP- and secondary antibody-labeled polymer reagent
method (Fig. 2d), where additional Protein block suppressed
non-specific binding of the polymer reagent and pretreat-
ment suppressed diffusion of the catalyzed biotinylated
or FITC-labeled tyramide (Fig. 2C, new simplified CSA
system) [28, 34].
The reagent for the Protein block was PBS containing
0.25% casein or 3% bovine serum albumin (BSA), dimin-
ishing non-specific staining of the primary antibody and
polymer reagents in the nsCSA system [28, 34]. It may have
been because the blocking reagent can mask most non-
specific binding sites, whereas competitive blocking by the
blocking reagent in the primary antibody and polymer
reagents would mask approximately half of all non-specific
binding sites. Catalyzed tyramide rarely diffused to be
deposited in areas distant from CARD reaction sites.
Pretreatment with biochemically inactive molecules was
required to achieve deposition of catalyzed tyramide much
nearer to the CARD reaction sites. The pretreatment reagent
was PBS containing 0.25% casein or PBS containing 3%
BSA and 0.1% Tween 20 for the biotinylated tyramide-
CARD reaction, while PBS containing 3% polyethylene
glycol (PEG) #20000 and 0.1% Tween 20 or PBS containing
0.3% BSA and 0.1% Tween 20 was employed for the FITC-
labeled tyramide-CARD reaction [28]. The nsCSA system
of the biotinylated tyramide-CARD reaction was free from
non-specific staining of endogenous biotin even in endog-
enous biotin-rich tissue such as that from the liver [28].
Antigen detection sensitivity was high in the following
order: nsCSA system with the biotinylated tyramide-CARD
reaction (Table 1C), nsCSA system with the FITC-labeled
tyramide-CARD reaction (Table 1C), and the Dako CSA II
system (Table 1B) with pretreatments diminishing non-
specific staining according to nsCSA system [28] because
the polymer reagent method (Fig. 2d) in the nsCSA system
was more sensitive than that of the HRP-labeled secondary
antibody method (Fig. 2a) in the CSA II system.
Protein block (PBS containing 0.25% casein, Dako)
was a powerful reagent in the nsCSA system but the
procedure, which exceeded 15 min, prevented antigen-
antibody reaction, whereas PBS containing 3% BSA did
not [28]. However, ultra-IHC employing PBS containing
3% BSA encountered non-specific staining through the
unexpected anti-BSA antibody that had contaminated the
secondary antibody reagent. Affinity-purified secondary
antibody reagent might be free from such contamination.
As mentioned in the following chapter of enzymatic-AR
and ultra-IHC of Tax, non-specific staining in B-cell
malignant lymphoma cells may be that of a part of an
antibody known as the Fc (Fragment, crystallizable) region.
This kind of non-specific staining cannot be suppressed by
the PBS containing 0.25% casein and the nsCSA system
may require additional Protein block with PBS containing
8% horse serum prior to the primary antibody reaction and
with PBS containing 8% goat serum prior to the secondary
antibody-polymer reagent reaction.
Furthermore, an adequate concentration of CARD
reaction-amplification reagent must be determined because
the amplification reagent of FITC-labeled tyramide from the
CSA II system yielded a larger amount of non-specific
staining than that of biotinylated tyramide from the nsCSA
system [28].Ultra-Super Sensitive IHC Applied to Etiological Study of ATLL 89
III. Application of Ultra-IHC of HTLV-1 Tax 
to Etiological Diagnosis of ATLL and 
Related Lesions
The pathogenicity of HTLV-1 infection that causes
ATLL is thought to be that of Tax, where Rex modulates
Tax expression and reproduction of HTLV-1 (Fig. 1) [110].
The molecular mechanisms in Tax pathogenicity have been
clarified and the target molecules of Tax are summarized
in Table 2 according to Grassmann et al. [23] and Watanabe
[106]. Recently, the pathogenicity of HBZ mRNA and
protein was analyzed [64, 65]. In addition, Tax, Rex and
HBZ proteins are thought to modulate the activation of
HTLV-1-proviral DNA and host genes together. Therefore,
Table 2. Targets and present form of HTLV-1 Tax
LTR: Long terminal repeat of HTLV-1 proviral DNA. CREB: Cyclic-AMP-response element binding protein. CRE: Cyclic-AMP responsive.
TATA box: Goldberg-Hogness box. TBP: TATA box-bound protein. CBP: CREB-binding protein. CAF: CBP-associated factor. NF-κB: Nuclear
factor kappa B. IKKg: I-kappaB-kinase gamma. IKKg=NEMO: NF-κB essential modulator. OX40=CD134: A member of the tumor necrosis fac-
tor (TNF)-receptor family and co-stimulatory T-cell molecule. OX40L: OX40 ligand. PI3K: Phosphoinositide 3-kinase. Akt=Protein kinase B
(PKB). ERK: Extracellular signal-regulated kinase. JNK: C-Jun NH2-terminal kinase. Cdk: Cyclin-dependent kinase. Rb protein: Retinoblastoma
protein. ChK: Checkpoint kinase. APC: Anaphase promoting complex. hDLG: Human DLG, a homologue of the Drosophila discs large PDZ
domain-containing tumor suppressor. BER: Base excision repair. NER: Nucleotide excision repair. hTERT: Human telomerase reverse
transcriptase.
Target Effect and present form of Tax References
HTLV-1
LTR Direct effect, forming a Tax-CREB-LTR’s CRE-motif 
complex.
[1, 10, 11, 91, 112]
Host cells
TBP Direct effect, forming a Tax-CBP complex or a 
Tax-p300-CAF complex with TBP.
[12, 14]
Signal transduction in host cells
NF-κB Direct binding, forming a Tax-IKKg (=NEMO) 
complex and a Tax-NF-κB-CBP complex
[15, 26, 41, 46]
IL-2 and IL-2 receptor (IL-2R) Indirect up-regulation [3, 7, 9, 22, 38, 66, 68, 81, 85]
IL-15 and IL-15 specific receptor (IL-15R) Indirect activation [8, 63]
IL-13 Indirect up-regulation [16, 103]
OX40 and OX40L Indirect up-regulation [78]
Transforming growth factor beta 1 (TGF-β1) Indirect repression [6, 54, 56]
Kinase-cascades in host cells
PI3K and its downstream target Akt Unclear [60]
ERK-JNK cascade Unclear [48, 107]
Cell cycle dysregulation in host cells
Cdk4, Cdk6 and Cdk2 Direct effect, forming a Tax-Cdk2/4/6 complex [24, 25, 43, 58, 72, 73]
Cdk inhibitors (p16INK4A, p15INK4B, p18INK4c, 
p19INK4d and p27Kip1)
Direct repression, forming Tax-p16INK4A and -p15INK4B 
complexes, and indirect suppression (p18INK4c, p19INK4d 
and p27Kip1)
[2, 43, 61, 93, 94]
Cyclin E Indirect up-regulation [39, 43, 83]
Cyclin D Indirect up-regulation [2, 20, 43, 69, 83]
Rb protein Direct effect, forming a Tax-Rb protein complex [52, 73]
E2F Indirect up-regulation [57, 75]
Cyclin A Indirect suppression [53]
ChK 1 and Chk 2 Indirect interaction [79]
APC Direct effect, forming a Tax-APC complex [59]
Cellular checkpoint protein MAD1 Direct effect, forming a Tax-MAD1 complex [44, 47]
Tumor suppressors and cellular apoptosis in host cells
p53 and p21Waf1/Cip1 Indirect or direct inactivation, forming a Tax-p300/CBP 
co-activator complex
[5, 102]
hDLG Direct effect, forming a Tax-hDLG complex [37, 95]
DNA repair and maintaining chromosomes in host cells
DNA polymerase β and BER Indirect suppression [45]
DNA polymerase δ, NER and mismatch repair. Indirect suppression [49]
BclxL that suppresses RAD51 recombination 
pathway, suppressing homologous recombination.
Induction [82]
hTERT Indirect induction [21, 90]Hasui et al. 90
the minimum target-molecules in ultra-IHC for etiological
diagnosis of ATLL were Tax and Rex, while the histochem-
istry of HBZ mRNA and protein is currently expected to be
established.
a) Modified ImmunoMax/CSA method for Tax and Rex on 
formalin-fixed paraffin-embedded sections
The rat monoclonal antibody against Tax, WATM-1
[100], mouse monoclonal antibody against Tax, Lt-4 [55],
and mouse monoclonal antibody against Rex, Rec-6 [30]
were supplied by Dr. Y. Tanaka (Table 3). Sections of
the HTLV-1-related cell line MT-2 were obtained from
formalin-fixed and paraffin-embedded cell pellets. ATLL
formalin-fixed paraffin-embedded sections were archival
pathology specimens of lymph nodes diagnosed as ATLL.
The modified ImmunoMax/CSA method was performed
by a semi-autostainer (MicroProbeTM, Fisher Scientific Co.)
[30, 31, 62]. Heating-AR was performed, heating sections
in 4 M urea solution by pressure cooking for 5 min [30].
Negative control staining was that of the primary antibody
reaction employing antibody dilution solution containing
no primary antibody.
By means of the heating-AR and ordinary sensitive
polymer method (Fig. 2d), only Lt-4 showed faint staining
in MT-2 while the other antibodies revealed no staining in
MT-2 and ATLL. By means of the heating-AR and modified
ImmunoMax/CSA method, in comparison with the negative
control (Fig. 3a), MT-2 indicated strong expression of
WATM-1-labeled Tax (Fig. 3b) and weak expression of
Rec-6-labeled Rex (Fig. 3c). In comparison with the nega-
tive control (Fig. 3d), ATLL exhibited weak expression of
WATM-1-labeled Tax (Fig. 3e) and obvious expression of
Rec-6-labeled Rex (Fig. 3f).
It was suggested that it is possible to detect Tax and
Rex on archival pathology specimen sections by means of
heating-AR and ultra-IHC. Moreover, it was indicated that
there was a difference in Tax and Rex expression pattern
between MT-2 and ATLL.
b) Application to case study of ATLL and related lesions
We identified HTLV-1-associated non-neoplastic
lymphadenopathy (HANNLA) in HTLV-1 carriers [33].
HANNLA demonstrated atypical follicular hyperplasia,
follicle-lysis,  and  enlarging  paracortex associated with
somewhat atypical lymphocytes [33]. Atypical follicles were
also noted in the tonsil of HTLV-1 carriers [97]. Gradual
increased expression of Lt-4 and WATM-1-labeled Tax
and high expression of Rec-6-labeled Rex was detected by
the heating-AR and modified ImmunoMax/CSA method
in atypical lymphocytes in the enlarged paracortex of
HANNLA, where marked expression of Ia-like antigen was
observed, and an increased number of HTLV-1 proviral
DNA copies were estimated semi-quantitatively from poly-
merase chain reaction (PCR) for HTLV-1 proviral DNA
and a host cell gene [30]. It was suggested that HTLV-1-
infected non-neoplastic T-cells expressed Tax and Rex in
the proliferative lesion, possibly related to occurrence of
anti-HTLV-1 immunity.
A smoldering type ATLL manifested as erythema in
the bilateral dorsal aspects of the upper arms, the fore chest,
the back, the abdomen, and the bilateral anterior aspects of
the thigh, and as hyperkeratotic erythema in the bilateral
aspects of the toes in a 76-year-old Japanese man. Biopsied
erythema in the left aspect of the thigh showed epidermo-
tropism of lymphocytes with their intraepidermal micro-
abscess formation (Fig. 4a), their perivascular infiltration in
the upper dermis (Fig. 4b) and their infiltration to hair
follicles (Fig. 4c). A biopsied lymph node in the left ingui-
nal region demonstrated dermatopathic lymphadenopathy
(DPLA) with hyperplastic lymph follicles and enlarged
paracortex (Fig. 4d) where atypical lymphocytes prolifer-
ated (Fig. 4e) and comprised CD4+ (Fig. 4f) CD8− T-cells.
Southern blot analysis of DNA extracted from the left
inguinal lymph node indicated monoclonal integration of
HTLV-1 proviral DNA (Fig. 4j), shown as 1 band in EcoR1
digestion, 3 HTLV-1 proviral DNA bands, and no detection
of 2 virus-cellular junction bands in Pst1 digestion. These
lesions  were  diagnosed  as  that  of  smoldering  ATLL.
The heating-AR and modified ImmunoMax/CSA method
showed that some ATLL cells proliferating in the paracortex
of the left inguinal lymph node expressed weakly WATM-
1-labeled Tax (Fig. 4h) and that many of them expressed
Rec-6-labeled Rex (Fig. 4i). It was suggested that prolifer-
ating ATLL cells in smoldering type expressed Tax weakly
and Rex strongly, identical to that of the ATLL in Figure 3.
ATLL initiating in the right palate tonsil and infiltrating
to the cervical and axillary lymph nodes was observed in a
51 year-old Japanese woman. She manifested swelling of
the right palate tonsil that showed diffuse proliferation of
small to medium-sized cells (Fig. 5a and b) with CD3+
CD4+ T-cell phenotype. One month later, a swollen right
palate tonsil and right cervical and axillary lymph nodes
(Fig. 5c) revealed infiltrative proliferation of medium-sized
to large CD3+ CD4+ CD30+ T-cells (Fig. 5d and e) with
developing background meshwork of thymidine phosphory-
lase (TP)+ dendritic cells (Fig. 5f). DNA extracted from the
right axillary lymph node indicated oligoclonal integration
of proviral DNA, shown as 2 bands in EcoR1 digestion, 3
proviral DNA bands, and 3 weakly labeled virus-cellular
junction bands in Pst1 digestion (Fig. 5j), which differed
from those of a defective HTLV-1 provirus [23, 99].
Rearrangement of T-cell receptor β was noted (Fig. 5k).
This case was an early phase of ATLL developing from
small- to medium-sized cells to pleomorphic cells with a
CD30+ activating phenotype. In the heating-AR and mod-
ified ImmunoMax/CSA method, most ATLL cells in early
phase ATLL in the right axillary lymph node showed
obvious expression of WATM-1-labeled Tax (Fig. 5h) and
much stronger expression of Rec-6-labeled Rex (Fig. 5i)
without obvious staining in the negative control (Fig. 5g),
suggesting that early ATLL cells with the activating pheno-
type expressed Tax in an obvious manner.
ATLL was also observed in Native Americans in
Argentina [62]. All 5 Native American ATLL cases demon-Ultra-Super Sensitive IHC Applied to Etiological Study of ATLL 91
Table 3. Antibodies that appeared in this review
*: Antigen retrieval heating in 0.01 M citrate buffer pH 6.
**: Antigen retrieval heating in 4 M urea solution by pressure cooking for 5 to 10 min in a draft.
***: Antigen retrieval treating sections by proteinase K solution for 10–30 min at room temperature.
****: Antigen retrieval heating in Diva Decloaker buffer (Biocare Medical) independent from pH of solution.
#1: Ordinary-IHC, super sensitive indirect enzyme-labeled antibody method (enzyme- and secondary antibody-labeled polymer reagent method).
#2: Ultra-IHC (Modified ImmunoMax/CSA method, possibly new simplified CSA system and Dako CSA II system modified according to the new
simplified CSA system).
#3: Ultra-IHC (New simplified CSA system).
Antigen Antibody Antigen retrieval Detection method
Used for diagnosis of lymphomas
CD3 NCL-CD3-PS1, Novocastra Heating* Ordinary-IHC #1
CD4 NCL-CD4-IF6, Novocastra Heating* Ordinary-IHC #1
CD8 M7103, Dako Heating* Ordinary-IHC #1
CD30 (Ber H2) M0751, Dako Heating* Ordinary-IHC #1
Thymidine phosphorylase (TP) Supplied from Dr. Akiyama S Heating* Ordinary-IHC #1
CD5 Leu 1, Becton Dickinson Heating** Ultra-IHC #2
Used for detecting HTLV-1 related proteins
HTLV-1 p40Tax Mouse mAb, Lt-4, supplied from Dr. Tanaka Y Heating*, Enzymatic*** Ultra-IHC #2,3
HTLV-1 p40Tax Rat mAb, WATM-1, supplied from Dr. Tanaka Y Heating*, Enzymatic*** Ultra-IHC #2,3
HTLV-1 p27Rex Mouse mAB, Rec-6, supplied from Dr. Tanaka Y Heating* Ultra-IHC #2
Used for detecting proliferation, cell cycle and DNA-damaged cell death
Ki67 antigen (MB-1) M7240, Dako Heating* Ultra-IHC #3
p53 NCL-p53-DO7, Novocastra Heating* Ultra-IHC #3
p53 phosphorylated NCL-p53-PHOS, Novocastra Heating* Ultra-IHC #3
E2F-1 sc193, Santa Cruz Heating** Ultra-IHC #2
E2F-4 sc511, Santa Cruz Heating** Ultra-IHC #2
DP-1 sc610, Santa Cruz Heating** Ultra-IHC #2
Cyclin E NCL-CYCLIN E, Novocastra Heating** Ultra-IHC #2
Used for detecting autophagy (autophagic vesicle nucleation)
Beclin-1 sc11427, Santa Cruz Enzymatic*** Ultra-IHC #3
Used for detecting stem cells, fetal cells, cancer cells and lymphoma cells
Survivin ab469, Abcam Heating**** Ordinary-IHC #1
CD117 NCL-CD117, Novocastra Heating* Ultra-IHC #3
Fig. 3. The modified ImmunoMax/
CSA method of Tax and Rex on par-
affin sections of MT-2 and 1 case of
lymphoma type ATLL (DAB-H2O2
reaction with methyl green nuclear
counterstaining. ×40, Olympus BX50,
FUJIFILM HC-300). a–c) MT-2. d–f)
ATLL.  a and d) Negative control
staining performed with antibody
dilution fluid containing no primary
antibody. b and e) WATM-1 (Tax).
c and f) Rec-6 (Rex). In comparison
with the negative control staining (a,
d) MT-2 cells show stronger Tax
staining (b) than ATLL (e) does,
although ATLL cells show stronger
Rex staining (f) than MT-2 (c) does.Hasui et al. 92
Fig. 4. Tax and Rex Expression in smoldering type ATLL (×40, Olympus BX50, FUJIFILM HC-300). a–e) Haematoxylin & Eosin (H.E.). a–c)
The left thigh showed intra-epidermal microabscess formation (a) and infiltration of small atypical lymphocytes around capillaries in the upper
dermis (b) and into the hair follicle (c). d–i) The left inguinal lymph node. d) Low power view (×10). e) High power view of the enlarged
paracortex. f) Ordinary-IHC of CD4 (DAB-H2O2 reaction and haematoxylin nuclear counterstaining). The left inguinal lymph node demon-
strates dermatopathic lymphadenopathy, of which the enlarged paracortex (d) indicates proliferation of atypical lymphocytes (e) positive for
CD4 (f). g–i) The modified ImmunoMax/CSA method (DAB-H2O2 reaction with methyl green nuclear counterstaining) for negative control
performed without primary antibody (g), WATM-1 for Tax (h), and Rec-6 for Rex (i). In comparison with the negative control staining (g)
some cells express Tax (WATM-1) weakly (h) and many cells express Rex (Rec-6) strongly (i). j) Southern-blot analysis of HTLV-1 proviral
DNA integration. 1) Positive control (ATLL cell line), 2) Negative control (human placental DNA), and 3) DNA extracted from the left
inguinal lymph node. E) EcoR1 digestion. Two DNA sequence (GAATTC) in cellular DNA on both ends of the HTLV-1 proviral DNA are
digested. P) Pst1 digestion. The DNA sequence (CTGCAG) in HTLV-1 proviral DNA and in cellular DNA on both ends of the HTLV-1
proviral DNA is digested into 3 proviral DNA bands of 1.2 kb, 1.8 kb, 2.5 kb and 2 virus-cellular junction bands. Positive control (1:
Monoclonal integration of HTLV-1 proviral DNA in ATLL cell line) shows 1 band labeled by a whole HTLV-1 proviral DNA probe in EcoR1
digestion and 3 proviral DNA bands and 2 virus-cellular junction bands in Pst1 digestion. The DNA extracted from the left inguinal lymph node
(3) indicates 1 weak band in EcoR1 digestion (arrow-head) and 3 weak bands of 1.2 kb, 1.8 kb, 2.5 kb in Pst1 digestion (arrows) while 2
virus-cellular junction bands are not recognized, suggesting monoclonal integration of HTLV-1 proviral DNA in some atypical cells.Ultra-Super Sensitive IHC Applied to Etiological Study of ATLL 93
Fig. 5. Tax and Rex expression in ATLL that initiated in the right palate tonsil and infiltrated to the cervical and axillary lymph nodes (×10 or
×40, Olympus BX50, FUJIFILM HC-300). a and b) First biopsy of the right palate tonsil (H.E.) showing diffuse proliferation of medium-sized
ATLL cells (a, ×10) and their tropism to the tonsillar epithelia (b). c–i) Second biopsy of the right axillary lymph node. c) Diffuse proliferation
of pleomorphic ATLL cells can be observed (H.E.). d–f) Ordinary-IHC of CD4 (d), CD30 (e) and thymidine phosphorylase (TP, f) (DAB-H2O2
reaction and haematoxylin nuclear counterstaining). Most of the pleomorphic ATLL cells are CD4 T-cells (d), some of them express CD30 (e),
and associate symbiotic growth of TP-positive dendritic cells forming a meshwork. g–i) The modified ImmunoMax/CSA method for the nega-
tive control (g), WATM-1 for Tax (h), and Rec-6 for Rex (i) (DAB-H2O2 reaction and haematoxylin nuclear counterstaining). In comparison
with the negative control staining (g), expression of Tax (WATM-1) (h) and strong expression of Rex (Rec-6) (i) are detected in the pleomor-
phic ATLL cells. j) Southern-blot analysis of HTLV-1 proviral DNA integration. 1) Positive control (ATLL cell line), 2) Negative control
(human placental DNA), and 3) Sample: DNA extracted from the left axillary lymph node. E) EcoR1 digestion. P) Pst1 digestion. The extracted
DNA shows 2 DNA bands from EcoR1 digestion, and 3 proviral DNA bands (arrows) and 3 virus-cellular junction bands (arrow heads) from
Pst1 digestion, suggesting oligoclonal integration of proviral DNA in the ATLL cells. k) Southern-blot analysis of T-cell receptor β (TCR β). 1)
BamH1 digestion. BamH1 digests the DNA sequence (GGATCC) in cellular DNA on both sides of the TCR β DNA sequence. 2) EcoRV
digestion. EcoRV digests the DNA sequence (GAATTC) in the TCR β DNA sequence. A rearranged TCR β band is observed in BamH1
(arrow) and EcoRV digestion (arrow) of the sample, suggesting that these pleomorphic ATLL cells are monoclonal αβ T-cells.Hasui et al. 94
strated obvious Tax and strong Rex expression, respectively,
in archival sections of pathology specimens tested by the
heating-AR and modified ImmunoMax/CSA method using
WATM-1 and Rec-6 [62]. However, 2 of 9 Kagoshima
ATLL cases did not demonstrate positive staining of
WATM-1-labeled Tax with the heating-AR and modified
ImmunoMax/CSA method (Table 4).
Clinically, approximately half of all ATLL cases are
leukemia, and the patients’ lymph nodes were usually not
examined pathologically. A lump of naturally precipitated
and coagulated peripheral blood can be processed into a
formalin-fixed and paraffin-embedded specimen, i.e.,
peripheral blood tissue specimen (PBTS) [35]. Leukemic
ATLL cells in the PBTS can be examined in the same
manner as those in archival pathology specimens. In PBTS
of 6 of 8 leukemic type ATLL cases comprising 4 chronic
and 4 acute leukemia type cases, Tax and Rex were detected
weakly and strongly, respectively, in a few or some ATLL
cells with the heating-AR and modified ImmunoMax/CSA
method using WATM-1 and Rec-6 [35].
HTLV-1-infected T-cells in the proliferative lesion in
the paracortex of HANNLA and ATLL cells proliferating
in the paracortex of DPLA in smoldering ATLL and in the
lymph nodes in early phase lymphoma type ATLL and in
lymphoma type ATLL in Native Americans and in Japanese
(Kagoshima natives) expressed Tax weakly and Rex strong-
ly with the heating-AR and modified ImmunoMax/CSA
method. Tax expression was correlated to Ki67 antigen+
proliferating cells in PBTS of leukemia type ATLL [35]. A
present form of Tax retrieved by heating AR and detected
with the modified ImmunoMax/CSA method of WATM-1
against Tax may be related with ATLL cell proliferation.
c) Enzymatic-AR and ultra-IHC of Tax
Tax is synthesized from the integrated HTLV-1 pro-
viral DNA pX region. As listed in Table 2, Tax forms a
complex  with cyclic-AMP-response element binding pro-
tein  (CREB),  docks at cyclic-AMP responsive (CRE)-
motifs of the HTLV-1 proviral DNA long terminal repeat
(LTR) and up-regulates Tax synthesis [1, 10, 11, 42, 91,
112]. On the other hand, Tax binds directly TATA box-
bound protein (TBP), recruits CREB-binding protein (CBP),
p300 and p300/CBP-associated factor (P/CAF) and forms
Tax-CBP-p300 and Tax-P/CAF complexes [12, 14], trans-
activating or -suppressing host cells genes. Besides, Tax
binds directly I-kappaB-kinase gamma (IKKg, =NEMO:
NF-κB essential modulator) and indirectly up-regulation
of Nuclear factor kappa B (NF-κB), effecting down-stream
Table 4. Evaluation of E2F, DP-1 and cyclin E in MT-2, ATLL and peripheral T-cell lymphomas in Europeans (EPTL), detected by the heating-
AR and modified ImmunoMax/CSA method
ATLL: Adult T-cell leukemia, lymphoma type. EPTL: Peripheral T-cell lymphoma in European, diagnosed in Dept. of Pathology (Prof. Martin-Leo
Hansmann), Johann Wolfgang Goethe-Universität Frankfurt am Main.
[HTLV-1 proviral DNA] Integrated: HTLV-1 proviral DNA was shown to be integrated in lymphoma cells. n.e.: Not examined.
Evaluation of the immunostainig of the modified ImmunoMax/CSA method of Tax, Rex, E2F-1, E2F-4, DP-1, and Cyclin E. –: Not positive cells.
+/−: Rare very weakly positive cells. +: A few weakly positive cells. ++: Some moderately positive cells. +++: Many strongly positive cells. ++++:
Almost all very strongly positive cells. n.e.: Not examined.
ATLL Tax vs. Cyclin E: Wilcoxon signed-ranks test, p=0.0209.
HTLV-1 E2F
DP-1 Cyclin E
Proviral DNA Tax Rex E2F-1 E2F-4
MT-2 integrated +++ ++ − ++ +++ −
ATLL 1 integrated + +++ − +++ +++ ++
ATLL 2 integrated + +++ −− +++ ++
ATLL 3 integrated + ++ −− ++ ++
ATLL 4 integrated + ++ −− ++ ++
ATLL 5 integrated +/− ++++ + − ++ +
ATLL 6 integrated +/− ++ −− +/−−
ATLL 7 integrated +/− ++ −− ++ +
ATLL 8 integrated − +++ +++ − +++ +
ATLL 9 integrated − +++ – ++ − +
EPTL 1 n.e. n.e. n.e. +++ +++ ++ ++
EPTL 2 n.e. n.e. n.e. ++ +/− +++ +++
EPTL 3 n.e. n.e. n.e. ++ + +++ +++
EPTL 4 n.e. n.e. n.e. + +/− ++ +++
EPTL 5 n.e. n.e. n.e. + – +++ ++
EPTL 6 n.e. n.e. n.e. +/− +/− +++ +++
EPTL 7 n.e. n.e. n.e. – +/− +++ +++
EPTL 8 n.e. n.e. n.e. +/−−+++ ++
EPTL 9 n.e. n.e. n.e. −− +++ +Ultra-Super Sensitive IHC Applied to Etiological Study of ATLL 95
signal transductions and their products [15, 26, 41, 46].
Tax binds directly cyclin-dependent kinases 2, 4, and 6
(Cdk2, Cdk4 and Cdk6) [24, 25, 43, 58, 72, 73] and Cdk
inhibitors (p16INK4A and p15INK4B) and indirectly suppresses
the other Cdk inhibitors (p18INK4c, p19INK4d, and p27Kip1) [2,
43, 61, 93, 94]. Tax binds also directly retinoblastoma (Rb)
protein [52, 73], anaphase promoting complex (APC) [59],
cellular checkpoint protein MAD1 [44, 47], and human
DLG, a homologue of the Drosophila discs large PDZ
domain-containing tumor suppressor [37, 95]. There are at
least 2 present forms of Tax, a simple present form (Free
Tax molecule, Fig. 6) and a complex present form (Tax
molecule in a complex, Fig. 6) that comprises the compli-
cated complexes mentioned above (Fig. 6). The efficiency
of AR on antigens in the Tax molecule may depend on its
present form in HTLV-1-infected T-cells. Heating-AR in
the modified ImmunoMax/CSA method of WATM-1
would expose the simple present form of Tax to the anti-
Tax antibody WATM-1. On the other hand, enzymatic-AR
digests the simple present form of Tax, some molecules
masking Tax in the complicated complexes and tissues
around Tax to expose Tax to the primary antibody, as sug-
gested in ultra-IHC of beclin-1 (Table 3) [50, 104]. In
order to detect the complex form of Tax, we employed
enzymatic-AR treating sections with 200 μg/mL proteinase
K solution for 10–30 min at room temperature and nsCSA
system (Table 1C, Fig. 2g) [28, 34].
The enzymatic-AR and nsCSA system (Table 1Ca)
visualized immunostaining that was more obviously granu-
lar with Lt-4 than with WATM-1 in some lymphocytes of
HTLV-1 carriers (Fig. 7a and b) and ATLL cells (Fig. 7c–
f) in PBTS. Chronic leukemia type ATLL (Fig. 7c and d)
exhibited granular Lt-4 immunostaining in more cells than
HTLV-1 carriers (Fig. 7a and b) and acute leukemia type
ATLL (Fig. 7e and f) (Table 5, Kruskal-Wallis test,
p=0.0388). Chronic ATLL cells may depend more on Tax
than acute type ATLL cells and HTLV-1-infected cells in
HTLV-1 carriers, suggesting the possibility that Tax main-
tains chronic type ATLL cells. However, non-specific dense
nuclear staining with Lt-4 and WATM-1 was observed in
an acute myelogenous leukemia (AML) patient without
antibodies against HTLV-1 (Fig. 7g and h). Based on
hematological diagnosis of peripheral T-cell leukemia,
HTLV-1 infection in leukemic cells could be detected in
PBTS by the enzymatic-AR and nsCSA system of Lt-4 for
Tax. Peripheral T-cell leukemia with Lt-4-labeled leukemia
cells has to be diagnosed as ATLL.
The enzymatic-AR and nsCSA system of Lt-4 was
applied to paraffin sections of 29 malignant lymphoma cases
diagnosed in a hospital’s Department of Pathology. Thirteen
of 14 PTCL cases were diagnosed pathologically as ATLL
based on clinical information regarding anti-HTLV-1 anti-
bodies in the serum or the integration of HTLV-1 proviral
DNA in lymphoma cells (Table 6).
As shown in Figure 8, a small number of ATLL cells
displayed obvious granular Lt-4 staining in all 13 ATLL
cases. Pleomorphic large lymphoma cells of PTCL not-
otherwise specified (PTCL NOS) displayed obvious granu-
lar Lt-4 staining (Fig. 8b). Since the Lt-4 immunostaining
provided information regarding HTLV-1 infection, this
Fig. 6. Present forms of Tax in a HTLV-1 infected T-cell. Tax is synthesized in the cytoplasm based on spliced one of RNAs from the HTLV-1
proviral DNA, often binding other molecules such as IκB in the cytoplasm and cAMP responsive element binding (CREB), DNA, and
chromosomes in the nucleus to manifest its pathogenicity. There are at least 2 present forms of Tax, a simple form existing freely or in a simple
complex with other molecules, and a complex form forming a complicated complex with other molecules.Hasui et al. 96
PTCL NOS could be diagnosed as ATLL. The enzymatic-
AR and nsCSA system of Lt-4 was informative for HTLV-
1 infection even in cases dominated by medium-sized cells
(Fig. 8e). In an ATLL case, a medium-sized cell exhibited
granular Lt-4 immunostaining localized in the cytoplasm,
and a large cell facing the medium-sized cells revealed faint
Lt-4 immunostaining in the cytoplasm (Fig. 8f). This figure
possibly suggested an image of HTLV-1 infection through
viral synapse [40]. The positive immunostaining of the
enzymatic-AR and nsCSA system of Lt-4 in background
cells (Table 6) suggested a possibility of secondary ATLL
from other lymphomas [32, 74], especially Hodgkin lym-
phomas [74].
Non-specific immunostaining in the enzymatic-AR and
nsCSA system of Lt-4 was noted in 11 cases of B-cell
neoplasm/malignant lymphoma (BML) (Table 6) and could
be differentiated from the specific granular Lt-4 immuno-
staining in ATLL. Nuclear staining was observed in 5 cases
of follicular lymphomas (FL, Fig. 9a) and in 1 case of B-
cell chronic lymphocytic leukemia (B-CLL), as well as in
PBTS of AML (Fig. 7g). Cytoplasmic fine staining was
observed in 1 case each of FL and diffuse large B-cell
lymphoma (DLBCL, Fig. 9b). Nucleolar staining was
observed in 2 DLBCL cases (Fig. 9c). In addition, dense,
clustered granule-like cytoplasmic staining was observed in
1 case of lymphoplasmacytic lymphoma (LP, Fig. 9d).
The non-specific nuclear staining in the enzymatic-AR
and nsCSA system of Lt-4 and WATM-1 may have been
that of the primary antibody. It may be possible to diminish
the nuclear staining by employing Protein block containing
8% horse serum as was done with the modified Immuno-
Max/CSA method. However, the modified ImmunoMax/
Fig. 7. Tax expression detected by the enzymatic-AR
and nsCSA system in peripheral blood tissue specimen
(PBTS) (DAB-H2O2 reaction and haematoxylin nuclear
counterstaining,  ×100 oil (×2.5 digital), Olympus
BX50, FUJIFILM HC-300). a and b) HTLV-1 carrier.
c and d) Chronic type ATLL. e and f) Acute type
ATLL. g and h) Acute myelogenous leukemia (AML).
More obvious granular immunostaining is seen in Lt-4
(a, c and e) than in WATM-1 (b, d and f) in HTLV-1
carriers, and chronic and acute type ATLL. However,
nuclear staining by Lt-4 (g) and WATM-1 (h) is noted
in an AML patient without antibodies against HTLV-1.
Table 5. Enzymatic-AR and new simplified CSA system of Lt-4 against Tax in PBTS of HTLV-1 carriers, ATLL and the other leukemias
*: Kruskal-Wallis test, p=0.0388. **: Nuclear staining in some cells.
Positive cells in PBTS
No positive cells A few positive cells Some positive cells Many positive cells
HTLV-1 carrier* 0 0 2 0
Chronic type ATL* 0 0 4 3
Acute type ATL* 0 3 3 0
The other leukemias 2 0 3** 0Ultra-Super Sensitive IHC Applied to Etiological Study of ATLL 97
CSA method of Lt-4 labeled the nuclei of epidermal squa-
mous cells [31]. Since nuclear staining, differing from
the granular staining in the nucleus, was often seen in
leukemia and lymphoma other than ATLL, such Lt-4 and
WATM-1 nuclear staining would not be related to HTLV-
1 pathogenicity.
The nucleolar and cytoplasmic non-specific immuno-
staining in BML was thought to be that of the secondary
antibody reagent, although rare HTLV-1-related BML might
exist. The secondary antibody reagent is usually goat
polyclonal antibodies against immunoglobulin (Ig) G1 from
a species of the primary antibody, and often includes a
relatively low amount of antibodies against IgG Fc region
and BSA (Hapten carrier protein). Nucleolar and cytoplas-
mic non-specific immunostaining would be diminished if
Protein block employing a solution of 8% serum from the
secondary antibody species (PBS containing 8% goat serum
and 0.25% casein) was carried out prior to the HRP- and
secondary antibody-labeled polymer reagent reaction (step
10 in Table 1C). On the other hand, an affinity-purified
secondary antibody reagent is also expected to diminish
nucleolar and cytoplasmic non-specific immunostaining in
the nsCSA system employing the serum-free Protein block.
The obvious granular immunostaining in the enzy-
matic-AR and nsCSA system of Lt-4 was thought to be
pathognomonic for ATLL. Thus, the enzymatic-AR and
nsCSA system of Lt-4 was expected to be a useful tool for
the etiological pathological diagnosis of ATLL, considering
the pathogenicity of Tax.
IV. Application of Ultra-IHC to Analysis of 
ATLL Oncogenesis and Pathogenesis
Oncogenesis and pathogenesis of ATLL can be under-
stood conceptually from the viewpoint of HTLV-1 patho-
genicity, as shown in Figure 1. HTLV-1 pathogenicity has
usually been investigated by means of molecular biology/
virology and fruitful results have been reported. It is also
studied from a genetic immunological viewpoint because
ATLL develops in a host that is immunologically compro-
mised against HTLV-1 infection. It is usually difficult to
examine pre-neoplastic phase and early-phase lesions of
ATLL pathologically. However, fortunately, as mentioned
above, we were able to carry out trials to detect HTLV-1
related molecules by means of ultra-IHC in HANNLA,
smoldering ATLL, early phase ATLL and developed/
lymphoma type ATLL. Moreover, we developed the PBTS
method [35] to prepare sections of peripheral blood
mononuclear cells (PBMCs) for IHC. Thus, we were able
to examine PBMCs in HTLV-1 carriers and leukemic ATLL
cells.
We recognized HANNLA [33] as displaying atypical
follicular hyperplasia with irregularly-shaped germinal cen-
ters (GCs) and enlarged paracortex. It is possible that some
HTLV-1-infected regulatory T-cells were related to the
irregularly-shaped GCs [33, 97]. In the enlarged paracortex,
atypical lymphocytes expressed Tax weakly and Rex
strongly with Ia-like antigen+ cells, while the extracted DNA
suggested increased copies of HTLV-1 proviral DNA,
suggesting that the enlarged paracortex of HANNLA was
Table 6. Enzymatic-AR and new simplified CSA system of Lt-4 applied to paraffin sections of malignant lymphomas
[T/NK-cell neoplasm/malignant lymphoma: TML] ATLL: Adult T-cell leukemia/lymphoma. PTCL, NOS: Peripheral T-cell lymphoma, not-
otherwise specified. EATL: Enteropathy-associated T-cell lymphoma. Extranodal NKTCL: Extranodal NK/T-cell lymphoma.
[B-cell neoplasm/malignant lymphoma: BML] FL: Follicular lymphoma. DLBCL: Diffuse large B-cell lymphoma. LP: B-cell lymphoplasmacytic
lymphoma. B-CLL: B-cell chronic lymphocytic leukemia.
#: Non-specific immunostaining was noted in 11 cases of BML in total. Non-specific nuclear staining was seen in 5 FL and 1 B-CLL. Non-specific
nucleolar staining was in 2 DLBCL. Non-specific cytoplasmal fine staining was in 1 FL and 1 DLBCL. Non-specific cytoplasmal dense staining
was in 1 LP.
Immunostaining
n Negative Positive background cells Positive lymphoma cells
T/NK-cell neoplasm (TML) 16 0 2 14
ATLL 13 0 0 13
PTCL, NOS 1 0 0 1
EATL 1 0 1 0
Extranodal NKTCL 1 0 1 0
B-cell neoplasm (BML) 12 1 0 11#
FL 7 1 0 6#
DLBCL 3 0 0 3#
LP 1 0 0 1#
B-CLL 1 0 0 1#
Hodgkin lymphoma (HD)
Mixed cellularity classic HD 0 0 1 0
Total 29 1 3 25 (11#)Hasui et al. 98
Fig. 8. Tax expression detected by the enzy-
matic-AR and nsCSA system of Lt-4 in
archival paraffin specimens of peripheral T-
cell lymphomas with and without clinical
information regarding HTLV-1 infection
(ATLL and PTCL) (DAB-H2O2 reaction and
haematoxylin nuclear counterstaining, ×100
oil, Olympus BX50, FUJIFILM HC-300).
More or less granular Lt-4 staining is noted
in the nucleus and cytoplasm. Variously-
sized pleomorphic lymphoma cells in ATLL
(a, c–e) and PTCL (b) show dominantly
intranuclear granular Lt-4 staining. Medium-
sized and large ATLL cells show cytoplas-
mic Lt-4 staining in cells facing one another
(f, arrow head). As Lt-4 staining in PTCL
cells (b) provides immunohistochemical
information of HTLV-1 infection, this case
might be diagnosed pathologically as ATLL.
Fig. 9. Non-specific  staining  in  the  enzy-
matic AR and nsCSA system of Lt-4 in
archival paraffin specimens of B-cell neo-
plasms (DAB-H2O2 reaction and haemato-
xylin nuclear counterstaining, ×100 oil,
Olympus BX50, FUJIFILM HC-300). a) Nu-
clear staining in follicular lymphoma (FL).
b) Fine granular staining in diffuse large
B-cell lymphoma (DLBCL). c) Nucleolar
staining in DLBCL. d) Dense cytoplasmic
staining in lymphoplasmacytic lymphoma/
immunocytoma (LP).Ultra-Super Sensitive IHC Applied to Etiological Study of ATLL 99
the site where occurred anti-HTLV-1 immunity and expan-
sive HTLV-1 infection in the atypical lymphocytes [30] that
maintained a viral load in PBMCs. Tax (Lt-4 or WATM-
1)-positive lymphocytes in the PBTS of HTLV-1 carriers
(Fig. 7a and b) may be HTLV-1-infected T-cells circulating
from HANNLA-like lesions in the lymphoreticular system.
It is difficult to label individual early neoplastic HTLV-
1-infected T-cells but IHC of survivin (Table 3) may suc-
ceed in this aspect [104]. Mutagens other than Tax, such
as APOBEC3G (apolipoprotein B mRNA-editing, enzyme-
catalytic, polypeptide-like 3G) [19], would precede neo-
plastic changes such as over-expression of TSLC1 (tumor
suppressor in lung cancer 1) [84] independently from Tax
in pre-ATLL cells. DNA damages induced by such mutagens
may be removed by the p53 protein system when HTLV-1
inactivates the p53 protein by phosphorylating it [80], and
Tax abrogates p53-induced cell cycle arrest and apoptosis
through its CREB/activating transcription factor (ATF)
Fig. 10. Expression of Ki67 antigen, p53 protein (p53) and phosphorylated p53 protein (phos-p53) detected by the heating-AR and nsCSA
system on the PBTS of HTLV-1 carriers and ATLLs (DAB-H2O2 reaction and haematoxylin nuclear counterstaining, ×40 and digital ×2,
Olympus BX50, FUJIFILM HC-300). a–c) HTLV-1 carriers. d) Chronic type ATLL. e) Acute type ATLL. 1) Ki67 antigen. 2) p53. 3)
phos-p53. Gradual increase of Ki67 antigen+ cells in PBTS is noted in HTLV-1 carriers (a1–c1) and most of chronic and acute type ATLLs.
Most leukemic ATLL cells were positive for Ki67 antigen (d1 and e1). Physiological expression of p53 in the cytoplasm and nucleus is detected
by the heating-AR and nsCSA system in HTLV-1 carriers (c2) and chronic type ATLL (d2), while dense nuclear expression of probable
mutated p53 is noted in acute type ATLL (e2), suggesting the possibility of differentiating acute from chronic type ATLL by detecting
dense nuclear expression of p53. On the other hand, phos-p53 is observed in HTLV-1 carriers (b3 and c3) and ATLL (d3 and e3), suggesting
the possibility of detecting HTLV-1 proviral DNA activity to inactivate p53-mediated DNA damage-induced cell death, since HTLV-1
inactivates p53 by phosphorylating Ser392 in its non-specific DNA binding or oligomerization domains. The immunostaining of p53 in b2 is
similar to that of phos-p53 in b3, indicating that phosphorylated p53 is detected by the anti-p53 antibody, and is different from that in c2. Thus,
the immunostaining of p53 in b2 is evaluated as negative.Hasui et al. 100
functional domain [70], prevents repair of damaged DNA
by suppressing DNA polymerases β [45] and δ [49] and
BclxL [82] (Table 2). It is well known that mutated p53
protein that has accumulated in the nucleus is detected by
ordinary-IHC in archival pathology specimens. We wanted
to observe physiological expression of p53 protein so that
we examined Ki67 antigen (Table 3) for proliferating cells,
p53 protein and p53 protein phosphorylated at Ser392 in
non-specific DNA binding domain (phos-p53) (Table 3) in
PBTS of HTLV-1 carriers and ATLL by means of the heat-
ing-AR and nsCSA system (Fig. 10). A gradual increase of
Ki67 antigen+ proliferating cells and gradual enhanced
expression of p53 protein and phos-p53 were observed in
HTLV-1 carriers. The gradual increase of Ki67 antigen+
proliferating cells might be due to the effects of Tax and
HBZ mRNA [64, 65] in PBMCs of HTLV-1 carriers. Weak
detection of p53 protein was dominant in the PBMCs’
cytoplasm of HTLV-1 carriers (Fig. 10 c2) and chronic type
ATLL (Fig. 10 d2). This weak cytoplasmic immunostaining
of the p53 protein was believed to be its physiological
expression. Dense nuclear staining of the p53 protein,
probably a mutant p53 protein, was observed in acute type
ATLL (Fig. 10 e2) as reported previously [105], suggesting
a possible standpoint for bone marrow transplantation
therapy in acute type ATLL [77]. After categorizing 8
HTLV-1 carriers in to 3 groups, i.e., p53− phos-p53− (2
cases, Fig. 10 a2 and a3), p53− phos-p53+ (3 cases, Fig. 10
b2 and b3) and p53+ phos-p53+ (3 cases, Fig. 10 c2 and
c3), we determined that there was a significant difference
in age among the 3 groups (mean ages: 32, 45 and 50
years, Kruskal-Wallis test p=0.049), indicating physiologi-
cal expression of the p53 protein (Fig. 10 c2) against accu-
mulation of DNA damages/mutations according to age and
inactivation of p53 by HTLV-1 infection [70, 80]. The
immunostaining of p53 protein (Fig. 10 b2) was similar to
that of phos-P53 (Fig. 10 b3) in PBMCs in the PBTS of
carrier B, but differed from that of the p53 protein (Fig. 10
c2 and d2) in carrier C and chronic type ATLL, suggesting
that immunostaining of the p53 protein (Fig. 10 b2) was
that of phos-p53. In addition, the appearance of phos-p53
in PBMCs might suggest the initial phase of ATLL onco-
genesis, since Tax inactivates the p53 protein by phospho-
rylating it [70, 80]. Further studies on the expression of
neoplastic features such as survivin [13] and human telom-
erase reverse transcriptase (hTERT) [21, 90] and that of
mutagens such as APOBEC3G [19] are necessary to eval-
uate oncogenetic advances in the p53− phos-p53+ and p53+
phos-p53+ stages of HTLV-1 carriers. Specific approaches
Fig. 11. Effects of Tax and HBZ mRNA molecular mechanism on cell cycle. Tax trans-scripted from the + strand of HTLV-1 proviral DNA
trans-activates several genes, targets several molecules in signal transduction as listed in Table 2, and produces proliferation signals to initiate
the G1 phase, cyclin E related to G1 progression, and cyclin D related to G1–S transition with stimuli from Tax-related and Tax-unrelated
neoplastic changes. Tax suppresses p53, which propels for Rb to form a complex with E2F-DP-1, and suppresses p21Waf1/Cip1, which is
cyclin-dependent kinase inhibitor 1 suppressing the Cdk2-cyclin E and Cdk4/6-cyclin D complexes. Furthermore, Tax trans-activates E2F-1,
trans-suppresses p16INK4A, and stimulates Cdk4/6 into binding with cyclin D to release the E2F-DP-1 complex from the Rb complex to G1–S
transition. On the other hand, HBZ mRNA releases E2F-DP-1 to G1–S transition. Tax also degrades cyclin A to propel over-duplication of
DNA in the S phase and disrupts cyclin B to upset spindle assembly checkpoint.Ultra-Super Sensitive IHC Applied to Etiological Study of ATLL 101
to halting Tax in these stages of HTLV-1 infection seems
to be warranted because green tea has the effect of reducing
viral load in peripheral blood [92].
Expression of the simple present form of Tax detected
by heating-AR and modified ImmunoMax/CSA method of
WATM-1 was related with proliferation of probable HTLV-
1-infected T-cells in HANNLA and in smoldering type,
lymphoma type and leukemic ATLL cells, as mentioned
above. The molecular mechanisms of Tax, HBZ mRNA
and their effect on the cell cycle are illustrated in Figure
11. Tax transcripted from the + strand of HTLV-1 proviral
DNA trans-activates several genes [110], targets several
molecules in signal transduction as listed in Table 2, and
produces proliferation signals to initiate the G1 phase, cyclin
E-related to G1 progression, and cyclin D-related to G1–S
transition with stimuli from Tax-related and Tax-unrelated
neoplastic changes. Tax suppresses p53 [5, 70, 80, 102],
blocking Rb [52, 73] to form a complex with E2F-DP-1,
and suppresses p21Waf1/Cip1, which in turn suppresses the
Cdk2-cyclin E complex. Further, Tax trans-activates E2F-1
[110], -suppresses Cdk inhibitors such as p16INK4A [2, 43,
61, 93, 94], and binds Cdk4/6 [24, 25, 43, 58, 72, 73]
to bind with cyclin D to release the E2F-DP-1 complex
from Rb to G1–S transition, competing with the p53
protein that is inactivated by Tax [70, 80]. DP-1 is stabilized
by binding with SOCS-3 in the cytoplasm. On the other
hand, HBZ mRNA releases E2F-DP-1 to G1–S transition
[64, 65]. Additionally, Tax degrades cyclin A to propel
over-duplication of DNA [53] and binds anaphase promot-
ing complex (ABC) to disrupt cyclin B to upset spindle
assembly checkpoints [59]. In order to see features in cell
cycle in MT-2, 9 cases of lymphoma type ATLL with
monoclonal integration of HTLV-1 proviral DNA, and 9
cases of PTCL in Europeans (EPTL) free from HTLV-1
infection, we examined E2F-1 activator and E2F-4 sup-
pressor for G1–S transition, DP-1 [29], and cyclin E with
the heating-AR and modified ImmunoMax/CSA method
(Table 4). MT-2 expressed E2F-4 in an obvious manner in
the nuclei and DP-1 predominantly in the cytoplasm, but
not E2F-1 and cyclin E (Fig. 12a–d). ATLL expressed
E2F-1 or E2F-4 in the nuclei in spite of weak E2F-1
expression in the cytoplasm of some cells in 1 case (ATLL5
in Table 4), moderate DP-1 expression in the cytoplasm and
cyclin E in some cells (Fig. 12g and h, Table 4). In ATLL,
Tax expression detected by the heating-AR and modified
ImmunoMax/CSA method of WATM-1 revealed correla-
tion with cyclin E expression (Wilcoxon signed-ranks test,
p=0.0209) but did not suggest any relation to the expres-
sion of E2F-1, E2F-4, and DP-1 (Table 4), suggesting that
Tax expression was correlated with the proliferation of
lymphoma type ATLL cells. EPTL expressed both E2F-1
and E2F-4 in some cells weakly, but expressed DP-1 and
cyclin E strongly in most cells (Fig. 12i to l, Table 4). The
expression of E2F-1 and E2F-4 in EPTL was quite different
from that in ATLL and had no correlation with that of cyclin
E (Table 4). The molecular mechanism in the G1–S phase
Fig. 12. G1 phase progression and G1–S phase transition detected by a panel of antibodies against E2F-1, E2F-4, DP-1, and cyclin E by the
heating-AR and modified ImmunoMax/CSA method (DAB-H2O2 reaction and haematoxylin nuclear counterstaining, ×40 Olympus BX50,
FUJIFILM HC-300). a–d) MT-2. e–h) ATLL. i–l) Peripheral T-cell lymphoma in Europeans (EPTL). a, e, and i) E2F-1. b, f, and j) E2F-4.
c, g, and k) DP-1. d, h, and l) Cyclin E. The expression pattern of E2F-1 and E2F-4 is different between ATLL and EPTL. The expression
pattern of cyclin E is also different between ATLL and EPTL.Hasui et al. 102
transition may be damaged or neoplastic in ATLL, where
the obscure co-expression of E2F-1 and E2F-4 observed
in EPTL was thought to be their physiological expression.
The mechanism of HBZ mRNA activating E2F-1 to propel
the G1–S phase transition in the cell cycle of ATLL cells
[23, 64, 65] was not identified by the heating AR and
modified ImmunoMax/CSA method, although the method
could visualize physiological expression of E2F-1, E2F-4,
DP-1, and cyclin E. Further studies are necessary to
elucidate the pathogenicity of HBZ mRNA and protein in
ATLL.
Enzymatic-AR and nsCSA system of Lt-4 demonstrated
obvious granular staining in a smaller number of ATLL cells
than expected, as mentioned above, suggesting that the
undigested, probable complex present form of Tax may be
a feature of young ATLL cells derived from ATLL stem
cells [51]. Since the “stemness” of stem cells allows their
original features to be maintained, the dependency of early
ATLL cells on Tax would be a feature of ATLL stem cells.
Heating-AR and nsCSA system of CD117 [50] (Table 3)
might be one way of investigating ATLL stem cells. Further
studies are warranted to clarify the features of ATLL stem
cells.
V. The Future Prospects of Ultra-IHC
In light of the fact that ultra-IHC has now been
established. We introduce ultra-IHC into the field of human
archival pathology specimens. Recently, the intercalated
antibody-enhanced polymer (IAEP) method comprising the
primary mouse monoclonal antibody reaction, secondary
anti-mouse Ig rabbit polyclonal antibody, and anti-mouse
anti-rabbit Ig- and HRP-labeled polymer reagent reaction,
succeeded in detecting the over-expression of ALK-fusion
protein that could not labeled by ordinary-IHC [98].
However, it appears that the physiological expression of
some antigens is not detected by ordinary-IHC and IAEP
methods. Ultra-IHC could label the physiological expression
of the tumor-suppressor gene product, p53 protein, and cell
cycle-related molecules: E2F-1, E2F-4, DP-1, and cyclin E.
We demonstrated through ultra-IHC that the staining of its
physiological expression was different from that of inacti-
vated/phosphorylated p53 protein. We also demonstrated the
physiological expression patterns of E2F-1, E2F-4, DP-1,
and cyclin E in EPTL and their neoplastic and altered
expression patterns in ATLL. Therefore, ultra-IHC has the
capability to bring IHC of human archival pathology
specimens to the next level, where the physiological
expression and inactivation of several kinds of molecules
can be detected.
The pathogenicity of HTLV-1 was that of Tax, although
it is often stated that Tax is not expressed in ATLL. This
review reported that ultra-IHC could detect minute amount
of simple and complex present forms of Tax in ATLL cells,
suggesting that Tax is expressed in ATLL cells. We must
keep in mind that extremely small amounts of Tax could be
detected by ultra-IHC in most cases of ATLL that is reported
to indicate Tax-induced modes of signal transductions. Since
atypical lymphocytes in HANNLA and ATLL cells express
much less Tax than MT-2 cells [30], as mentioned above
and shown in Figure 3, the Tax-induced molecular events
listed in Table 2 have to be re-evaluated in the cases of high
and low Tax expression in HTLV-1 infected cells probably
under constant expression of HBZ mRNA and protein. The
molecular events induced by low Tax expression may play
roles in ATLL oncogenesis, which spans more than 30 years
under anti-HTLV-1 immunity.
In the field of hematopathology, PBTS is a powerful
archival pathology specimen, in which PBMCs can be
examined through histochemistry including ultra-IHC.
Ultra-IHC on PBTS is expected to enable monitoring of
various changes in PBMCs in ATLL oncogenesis.
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